Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
November 13, 2024 07:30 ET
|
Lexeo Therapeutics
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
June 03, 2024 07:05 ET
|
uniQure Inc.
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s...
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
December 03, 2019 08:30 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it...
Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy
September 24, 2019 07:30 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation
April 23, 2019 08:05 ET
|
ExCellThera
MONTREAL, April 23, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
November 12, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
The Alliance for Regenerative Medicine and Informa Pharma Intelligence to Host Regenerative Medicine Advanced Therapy Designation Webinar on June 13, 2018
May 29, 2018 12:09 ET
|
Alliance for Regenerative Medicine
WASHINGTON, D.C., May 29, 2018 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM) today announced it will co-host a webinar titled “RMAT Designation – Impact on the Regenerative...
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
April 23, 2018 08:15 ET
|
Abeona Therapeutics Inc.
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics...
Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy
February 05, 2018 11:11 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002, its lead investigational...
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
January 29, 2018 08:45 ET
|
Abeona Therapeutics Inc.
First gene therapy RMAT designation for Epidermolysis BullosaEnables accelerated approval path and real world data usage NEW YORK and CLEVELAND, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Abeona...